Human Carcinogenesis & Health Disparity Meeting (Speaker Bios)

Speaker Bios


  • Aldape Headshot.jpg
    kenneth Aldape, MD
    Senior Investigator, Laboratory of Pathology, NCI/CCR

    Dr. Aldape is a molecular neuropathologist with a focus on the molecular basis and classification of brain tumors. From a broader perspective, he is interested in the use of new technologies (genomic, computational) that contribute to precision diagnostics of cancer, and ultimately improved patient outcomes.

    Areas of Expertise
    1) molecular genomics of brain tumors 2) diagnostic neuropathology 3) precision diagnostics 4) epigenomic signatures of cancer

  • Stefan Ambs3.13.2021.jpg
    Stefan Ambs, PhD
    Senior Investigator, National Cancer Institute - National Institutes Of Health, United States

    Stefan Ambs is a tenured Senior Investigator at the National Cancer Institute and head of the Molecular Epidemiology Section, Laboratory of Human Carcinogenesis ( He has a research interest in the causes of prostate and breast cancer health disparities. His group utilizes epidemiological and translational research strategies to identify risk factors and pathways that define tumor development and progression, and the response to therapy. Their research includes discovery of biomarkers using genome-wide analysis of gene expression and evaluation of the tumor metabolome and proteome, inflammation and cancer, and the analysis of genetic variations and their association with cancer.

  • Carpten Headshot.jpg
    John D Carpten, Ph.D.
    Program Co-Leader, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California

    Dr. John D. Carpten currently serves Chair for the Department of Translational Genomics, and is the Royce and Mary Trotter Chair for Cancer Research, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA. He also serves as Associate Director of Basic Sciences for the USC Norris Comprehensive Cancer Center. Dr. Carpten studies multiple forms of cancer and is an expert in cancer genome science, cancer cell biology, and Precision Medicine, and has co-authored over 200 publications. He currently serves as a member of the Board of Directors for the American Association for Cancer Research, and the Scientific Advisory Boards for Stand Up to Cancer, and Break Through Cancer Foundation. Most recently, Dr. Carpten received a presidential appointment to serve as Chair for the National Cancer Advisory Board.

  • 2021_03_23_GALLE_Peter Robert_Foto Peter Pulkowski_0001_DSC3777.jpg
    Peter R Galle, M.D., Ph.D.
    Chairman, Universitätsmedizin Mainz

    Dr. Galle majored in internal medicine at the Universities of Berlin, Marburg, Mannheim and Heidelberg, Germany, at Hammersmith Hospital, London/UK and, as a Fulbright grantee at University of Texas/USA and received his M.D. degree from Marburg University and Ph.D. degree from Heidelberg University.

    Initially he held a position as postdoctoral fellow in Molecular Biology at the Centre for Molecular Biology Heidelberg working on the replication of hepatitis B viruses. Afterwards he completed his residency in Internal Medicine and Gastroenterology at the University Hospital of Heidelberg. In 1998 he became Director of the I. Medical Department in Mainz and from 2005 – 2008 he hold the CEO position of Mainz University Hospital.

    He is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), served as Co-editor for the Journal of Hepatology and was on the Editorial Boards of several other Journals. He served as congress president of the German Society for Digestive Diseases (DGVS) in 2014. He was member of the Executive Board and President of the International Liver Cancer Association (ILCA). He was the President of the German Association for the Study of the Liver (GASL) for the year 2020.

    His research has focused on elucidating important aspects of apoptotic cell death in the liver, immune escape of tumour cells and on clinical and molecular aspects of hepatocellular carcinoma (HCC). He chaired the panel updating the EASL Clinical Practice Guideline on HCC, which appeared in 2018. He was awarded several prizes, amongst others the prestigious Tannhauser award, the highest prize of the German Society for Digestive Diseases. He has published more than 550 peer-reviewed papers.

    Google Scholar Citation Report (JUL 2022)

    Sum of the Times Cited: 85,196
    h-index: 125

  • 2022_07_27_NCI-Dr Mark Gilbert-31.JPG
    Mark R. Gilbert, M.D.
    Chief & Senior Investigator, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Neuro-Oncology Branch

    Dr. Gilbert is the Chief and Senior investigator of the Neuro-Oncology Branch in Bethesda Maryland. His vision is to build a highly collaborative, robust translational research program centered on finding treatments for brain and other central nervous system tumors where basic research observations will be rapidly translated into pre-clinical testing and then hypothesis-based clinical research trials, including important correlative studies.
    Dr. Gilbert received his medical doctorate (M.D.) from Johns Hopkins University (JHU). At JHU, he completed residencies in internal medicine and neurology and fellowship training (Keck Foundation Fellowship) in both neurology and neuro-oncology. In 2000, after serving on the faculties of the University of Pittsburgh and Emory University, Dr. Gilbert joined the University of Texas MD Anderson Cancer Center as Deputy Chair of the Department of Neuro-oncology. In 2005, he was appointed as Director of the Brain Tumor Trials Collaborative, a multi-center clinical trials consortium. In 2009, Dr. Gilbert received the Blanche Bender Endowed Professorship in Cancer Research. Dr. Gilbert is also the founder and former leader of the Collaborative Ependymoma Research Network (CERN), a consortium studying ependymoma, a rare central nervous system cancer.

  • AMM-220516-1526.jpg
    Sharon A. Glynn, PhD, MPH
    Associate Professor in Pathology, Lambe Institute for Translational Research, University of Galway

    The central theme of my laboratory is to explore how inflammation derived from nitrosative stress and human endogenous retrovirus activation influences tumour biology, modifies the tumour microenvironment and influences treatment responses and patient outcomes. A major source of nitric oxide (NO) and nitrosative stress in tumours comes from inducible nitric oxide synthase (iNOS), and correlates with increased risk of poor outcomes and distant metastasis. Our research is exploring the pro- and anti-tumour effects of NO in cancer biology including cellular response to stressors such as DNA damage, oncogene activation, altered cell metabolism and deregulating DNA repair enzymes and tumour suppressor genes, in addition to modulation of apoptotic and metastatic processes.

    Our research also explores the role of HERV-K in tumour biology. HERV-K has been found to be activated in many tumour types including breast and prostate cancer, and is associated with increased risk of poor outcomes. Using in vitro models of breast and prostate cancer, we are examining the role of HERV-K derived proteins (Gag, Env, Rec and Np9) on tumour cell phenotype and signal transduction pathways. Coupled with our patient cohort studies this allows us to then validate our findings for clinical importance.

    Finally we also seek to understand the impact of these tumour epithelium expressed inflammatory mediators on the larger tumour microenvironment using 3D spheroid co-culture models and via multiplex protein and RNA imaging of tumours with our US based collaborators at the National Cancer Institute. Sharon has been awarded a number of grants including a Fulbright Scholar Award in 2022, Science Foundation Ireland (SFI) Career Development Award in 2018 , in addition to Breast Cancer Now Project and PhD Grants, and Irish Cancer Society Funding and is a CÚRAM SFI Research Centre for Medical Devices funded investigator.

  • Headshot.jpg
    Romina Goldzmid, PhD
    Stadtman Investigator and Head, Inflammatory Cell Dynamics Section. Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute (CCR-NCI).

    Dr. Goldszmid’s research is at the intersection of tumor immunology, myeloid cell biology, and immunity to infections. She is a Stadtman Investigator and head of the Inflammatory Cell Dynamics Section in the Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute (CCR-NCI). Dr. Goldszmid received her PhD from the University of Buenos Aires, Argentina, part of which was performed as a visiting student in the laboratory of Dr. Ralph Steinman at the Rockefeller University, working on dendritic cell-based vaccines for cancer immunotherapy. She then trained in infectious diseases immunology as a postdoctoral fellow in the Laboratory of Parasitic Diseases at the National Institute of Allergy and Infectious Diseases, NIH. After completing her postdoctoral training, Dr. Goldszmid returned to tumor immunology joining the Cancer and Inflammation Program at CCR-NCI, where she led pioneering work on the role of the gut microbiota in cancer therapy. Current work in her laboratory aims to dissect the myeloid cell repertoire within tumors, determine their contribution to therapy efficacy, and unravel the mechanisms by which microbiota regulates their function. Dr. Goldszmid is recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE), NCI Director’s Innovation Award, NCI CMAP Exceptional Mentor Award, among others.

  • Headshot.jpg
    Tim Greten, M.D.
    Senior Investigator, NCI

    Tim F. Greten, M.D., received his medical training at the Christian Albrechts University in Kiel, Germany. He did his internship in Munich followed by a 3-year postdoctoral fellowship at the Johns Hopkins University (Baltimore, Maryland), where he initiated his work in the field of tumor immunology. In 1999, Dr. Greten returned to Hannover Medical School, where he finished his training in Internal Medicine (2003), Medical Oncology (2004) and Gastroenterology (2007). He held an Associate Professor position in the Department of Gastroenterology, Hepatology and Endocrinology in Hannover Medical School. In February 2010, Dr. Greten joined CCR's Medical Oncology Branch as the head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015 and Deputy Branch Chief in 2018.
    Dr. Greten has published more than 200 peer-reviewed papers in different journals including Science, Nature, Cell, Cancer Cell, Cancer Discovery and New England Journal of Medicine. Dr. Greten is co-chair of the Center of Excellence in Immunology and co-director of the NCI CCR Liver Cancer Program.

  • Curts Headshot.jpg
    Curtis C Harris, M.D.
    Lab Chief, NCI

    Receiving his M.D. from Kansas University School of Medicine and his clinical training at both UCLA and the NCI. He has held positions of increasing responsibility at the NCI and is an Adjunct Professor of Oncology at Georgetown University School of Medicine. Receiving numerous honors including, e.g., the Alton Ochsner Award relating Smoking and Health (American College of Physicians), Deichmann Award (International Union of Toxicology), Charles Heidelberger Award (International Society of Gastroenterological Carcinogenesis), Distinguished Service Medal (highest honor of the U.S. Public Health Service), NCI Outstanding Mentor Award in 2007 and 2013, Ph.D. (Honorary) Nippon University School of Medicine in 2013. He was awarded the AACR-Princess Takamatsu Award in 2009, the ILCA Nelson Fausto Award and AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention in 2014. In 2016, he was awarded the Distinguished Medical Alumnus Award from Kansas University School of Medicine and in 2020, was awarded the Environmental Mutagenesis and Genome Society Annual Award. Fellow in the 2021 AACR Academy class. He also is a Fellow at the American Society of Clinical Investigation and AAAS. Publishing more than 700 journal articles, 100 book chapters, edited 10 books and holds more than 30 patents for the U.S. Government. Serves as Editor-in-Chief for the journal, Carcinogenesis, and has held/currently holds elected offices in scholarly societies and non-profit foundations including the AACR, the Keystone Symposia on Molecular and Cellular Biology and co-founder and President of the Aspen Cancer Conference. He has a wide range of scientific interests and accomplishments spanning molecular genetics and epigenetics of human cancer to molecular epidemiology of human cancer risk and mechanistic biomarkers of cancer diagnosis, prognosis, and therapeutic outcome. Harris has a long productive history of investigating the mutation and function of p53 and recently, p53 isoforms involvement in cellular reprogramming and senescence.

  • David Lane pic.jpg
    David P. Lane, Ph.D,
    Professor , Karolinska Institute

    Sir David is the Chairman of Chugai Pharmabody and a Professor at the Karolinska Institute in Stockholm. He was the Chief Scientist of A*STAR until 2021, where his main role was to advise and engage in scientific development across the Biomedical Research Council (BMRC) and the Science and Engineering Research Council (SERC) at the strategic level. He also ran a research lab primarily focusing on research on p53 using both mammalian and zebrafish systems. Sir David was recently appointed as the Chairman of the Scientific Committee that advises CRUK and NCI on the Cancer Grand Challenge. Sir David is best known for his discovery of the p53 protein and has published more than 400 research articles in international peer reviewed journals many of which have been very highly cited and has co-authored a successful practical guide to the development of monoclonal antibodies and the use of immunochemical methods called “Antibodies” with Ed Harlow, selling more than 40,000 copies. He is the founder of Cyclacel, a NASDAQ listed company with three drugs in Clinical trial. Sir David established the Experimental Therapeutics Centre at A*Star in 2007. He is a founder of AbAsia and FOG pharmaceuticals. He was formerly the Chief Scientist at Cancer Research UK and for three years the Scientific Director of the Ludwig Institute. He has been recognized for his work by many international awards including the Paul Ehrlich Prize, the Brucbacher Prize, the Buchanan Medal of the Royal Society and the Royal Medal of the Royal Society of Edinburgh. Last year he received the Singapore Presidents Science and Technology Medal for his contribution to the development of Science in the Republic.

  • Xin 200x250.jpg
    Xin Lu, Ph.D.
    Director, The Ludwig Institute for Cancer Research

    Professor Xin Lu is the Director of the Ludwig Institute for Cancer Research at the University of Oxford, UK. Xin Lu is a cancer biologist distinguished by her contributions to understanding cellular pathways that control cell fate in development and disease, particularly cancer. She has a long-standing interest in how to selectively kill cancer cells, and her major research advances have provided insights into how p53, the most mutated or inactivated tumour suppressor in human cancers, can make life or death decisions for a cell.

    In addition to her research, Xin plays a crucial role in helping to shape the cancer research landscape at Oxford through her Directorship of the Oxford Branch of the Ludwig Institute for Cancer Research, co-Directorship of the Cancer Research UK Oxford Centre, Cancer Theme leadership for the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, and Directorship of the Oxford Centre for Early Cancer Detection. Xin has recently been elected as a Fellow of the Royal Society, the UK’s distinguished academy of science, for her contributions to cancer biology. Xin is also a Fellow of the Academy of Medical Sciences and the Royal Society of Biology, a Fellow by election of the Royal College of Pathologists, and a Member of the European Molecular Biology Organisation.

  • Lichun Ma pic.JPG
    Lichun Ma, Ph.D.
    Investigator, Cancer Data Science Laboratory, NCI

    Dr. Ma received her Ph.D. degree in Electronic Engineering at the City University of Hong Kong in 2016. After a one-year postdoctoral fellowship at Nanyang Technological University, Singapore, she joined NCI in 2017 as a postdoctoral fellow where she studied cancer biology using single-cell techniques. She initiated her independent research program at NCI as a Stadtman Investigator in 2022. Dr. Ma has a strong background in mathematics, information theory and machine learning. She received many awards during her training, including the NCI CCR Excellence in Postdoctoral Research Transition award. Her recent work on tumor cell biodiversity and microenvironmental reprogramming in liver cancer was showcased in the 2019-2020 NCI Center for Cancer Research Milestones publication.

  • Selfie_EWy.jpg
    Ewy Mathé, Ph.D.
    Director of Informatics, Division of Preclinical Innovation, National Center for Advancing Translational Sciences

    Dr. Ewy Mathé is the Director of Informatics in the Division of Preclinical Innovation at NCATS. She received a Bachelor’s degree in Biochemistry (minor in Sociology) from Mount Saint Mary’s University, MD in 2000 and a PhD in Bioinformatics from George Mason University, VA in 2006. During her post-doctoral training with Dr. Curtis Harris (NCI/NIH), she discovered putative esophageal and lung cancer biomarkers using miRNA microarrays and metabolomics, leading to two patent applications. She then joined Dr. Rafael Casellas’ laboratory (NIAMS/NIH), where she aimed to better understand modalities of transcriptional regulation in B lymphocytes, using next-generation sequencing techniques. Since then, she has focused on developing methods and frameworks to guide analysis, integration, and interpretation of high-throughput sequencing and multi-omic data to uncover biological mechanisms and identify valid biomarkers and therapeutic targets for the diagnosis, prognosis, and treatment of various diseases. She is very active in the metabolomics community (Metabolomics of North America, Metabolomics Society, Consortium of Metabolomics Studies), and is a proponent of open-source software development and data.
    As Director of Informatics, she leads a diverse team of experts in bioinformatics, cheminformatics, data science, and software development that empower translational scientists to make meaningful data-driven decisions in their research. Her team is currently developing computational resources, methods and tools that optimize the use of large scale molecular (high throughput screening, multi-omics, etc.) and knowledge-driven datasets (various sources of information on drugs, including mechanisms of action, regulatory status, etc., drug targets, diseases, biological functions, etc).

  • ParkerAmelia_headshot.png
    Amelia Parker, Ph.D.
    Research Officer, Garvan Institute of Medical Research

    Amelia completed her Bachelor of Biomedical Engineering and Advanced Science (Biochemistry) degree at the University of Sydney before undertaking her Ph.D. training with the Children’s Cancer Institute and University of New South Wales investigating the role of microtubule proteins in lung cancer aggressiveness.
    Amelia furthered her interest in translational lung cancer research during her postdoctoral training at the Laboratory of Human Carcinogenesis, National Cancer Institute, USA under the mentorship of Dr Curtis Harris focussing on biomarkers and mechanisms of lung cancer progression.

    Currently at the Garvan Institute of Medical Research, Sydney, Australia, Amelia is leading the interdisciplinary lung cancer program within the Matrix and Metastasis lab led by A/Prof Thomas Cox. Her research aims to further our understanding of the role of the extracellular matrix in lung cancer development and aggressiveness, and reveal novel stromal-targeting strategies to enhance treatment efficacy in a precision medicine framework.

  • Andrea_200x250px.jpg
    Andrea Pfeifer, Ph.D.
    Co-Founder, Chief Executive Officer and Director, AC Immune SA

    Dr. Andrea Pfeifer co-founded AC Immune SA in 2003, successfully leading it to an IPO in 2016, since when she has served as a Director on the Board. Under her leadership, multiple transformative partnerships have been established with leading pharmaceutical companies, yielding a potential value of up to CHF 3.3 billion plus additional royalties.

    Before founding the Company, she was the Head of Nestlé Research Centre in Lausanne, Switzerland where she played a major role in connecting science and business. Whilst at Nestlé she led the scientific development of a number of highly innovative, critically acclaimed products from laboratory to market, established the microbiome as a major cross-category product development platform and co-founded the Life Science focused Nestlé Venture Capital Fund. Prior to this she was a Visiting Fellow at the Human Carcinogenesis Branch of The National Institute of Health, Bethesda, USA. She currently serves as the Chair of Investment Fund BioMedInvest, Basel and AB2 Bio SA, Lausanne, and is a member of the Supervisory Board of Symrise AG, Holzminden, Germany. She is also a key member of the CEOi initiative on Alzheimer’s Disease and the Davos Alzheimer’s Collaborative (DAC). In 2021, she was awarded the first SEF.WomenAward for CEO of the Year by the Swiss Economic Forum. In 2022, she received the Aenne Burda Award for Creative Leadership, recognizing her pioneering work in the field of neurodegenerative diseases.

    Dr. Pfeifer holds a Ph.D. in Toxicology (Cancer Research) from the University of Würzburg, Germany and is a registered Toxicologist and Pharmacist. She received her Habilitation from the University of Lausanne, Switzerland and is an Honorary Professor at the Ecole Polytechnique Fédérale de Lausanne (EPFL).

  • Pine_Sharon 2022.jpg
    Sharon R. Pine, Ph.D.
    Professor, University of Colorado School of Medicine, Division of Medical Oncology

    Dr. Sharon Pine graduated with a PhD in Experimental Pathology from New York Medical College and went on to her post-doctoral fellowship training with Dr. Curtis C. Harris in the Laboratory of Human Carcinogenesis at the National Institutes of Health, National Cancer Institute, where her research focused on cancer health disparities in lung cancer and lung cancer stem cells. She started her faculty appointment at Rutgers University in 2010 and moved up to the rank of Tenured Associate Professor in the Departments of Medicine and Pharmacology before starting her current position in July 2022 as Professor and Fred Hirsch Endowed Chair in Medical Oncology at the University of Colorado School of Medicine. She has been on the Leadership Board of the American Lung Association since 2016, served the Assistant Director for Research in the Center for Community Outreach and Engagement at the Rutgers Cancer Institute of New Jersey, and currently serves as Director of the Thoracic Oncology Research Initiative (TORI) at the University of Colorado Cancer Center. Dr. Pine's awards include the Brigid Leventhal Merit Award for the highest ranking abstract at the American Society of Clinical Oncology Annual Meeting, NIH Clinical Research Training Award, NCI K22 Career Development Award, Richard C. Devereaux Outstanding Young Investigator Award in Lung Cancer, and American Lung Association Lung Cancer Discovery Award. She serves on research grant review committees for the Department of Defense and National Cancer Institute and is on the editorial board for the journals Carcinogenesis, Frontiers in Oncology, and Physiological Genomics. She has published peer-reviewed articles in top-tier journals including Nature Cell Biology, Journal of Clinical Investigation, and Journal of Thoracic Oncology. Her current work focuses on lung cancer, with emphases on health disparities, stem cell signaling pathways, and discovery of novel targets for lung cancer therapy.

  • Roger Reddel 200x250 px.jpg
    Roger R. Reddel, M.B.B.S., Ph.D.
    Director, Children's Medical Research Institute, The University of Sydney

    Roger Reddel is the Executive Director of Children's Medical Research Institute (CMRI) and the Lorimer Dods Professor, Faculty of Medicine and Health, University of Sydney. His training included medical degrees from the University of Sydney, clinical training and board certification in medical oncology, a PhD in cancer cell biology, and postdoctoral research at the US National Cancer Institute's Laboratory of Human Carcinogenesis. His research at CMRI investigates the immortalization of cancer cells, and he and his team are best known for discoveries regarding the role of telomere length maintenance in immortalization, and especially the Alternative Lengthening of Telomeres mechanism. Roger is also a co-founder of the ProCan program, which is focussed on developing the technology and evidence base required to utilize proteomic data in the cancer clinic.

  • Rössler_Stephanie_DSC8034_small_200_250.jpg
    Stephanie Roessler, Ph.D.
    Research Group Leader, Heidelberg University Hospital

    Dr. Stephanie Roessler’s research focuses on the identification and functional characterization of molecular alterations involved in liver carcinogenesis. After her PhD work at the Max-Planck Institute of Immunology and Epigenetics (Freiburg, German), Dr. Roessler obtained postdoctoral training at the National Cancer Institute (Bethesda, MD) in the research group of Dr. Xin Wei Wang (Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis) performing integrative molecular profiling of hepatocellular carcinoma (HCC). In 2013, Dr. Roessler returned to Germany and established her own research group at the Institute of Pathology of Heidelberg University Hospital. Her research group aims at identifying genetic and epigenetic alterations in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) initiation and progression. Furthermore, the Roessler group utilizes in vivo and in vitro models to delineate the molecular mechanisms of liver cancer development and progression with potential application towards targeted therapies.

  • eytan_umiacs_picture.jpg
    Eytan Ruppin, M.D., Ph.D.
    Chief, Cancer Data Science Lab (CDSL) , CCR, NCI

    Eytan Ruppin received his M.D. and Ph.D. (Computer Science) from Tel-Aviv University where he has served as a professor of Computer Science & Medicine since 1995, conducting computational multi-disciplinary research spanning a wide variety of topics, including neuroscience, evolutionary computation, natural language processing, machine learning and systems biology. He joined the University of Maryland in July 2014 as a Computer Science professor and director of its center for bioinformatics and computational biology (CBCB), before joining the NCI in January 2018, where he founded and is Chief of its Cancer Data Science Lab. He is a member of the editorial board of EMBO Reports and Molecular Systems Biology, a fellow of the International Society for Computational Biology (ISCB), and has recently received the NCI Director award (2022) and the Delano Award for Computational Biosciences (2023) for his contributions for advancing transcriptomics based precision oncology. Dr. Ruppin is also a co-founder of a few startup companies involved in precision medicine and cancer drug discovery.

  • Headshot.jpg
    Brid M Ryan, Ph.D.
    Vice President of Oncology and Immunology Research , MiNA Therapeutics

    Bríd is Vice President of Oncology and Immunology Research at MiNA Therapeutics, leading pipeline research, biomarker, and pre-clinical programs. She previously spent 14 years at the LHC, where she was a Principal Investigator for eight years working on precision medicine and biomarkers in lung cancer, with a focus on population differences in tumour biology. Bríd also did her postdoc with Curt at LHC as a Cancer Prevention fellow.

    Bríd has a BSc Honours in Biochemistry from University College Cork, a PhD in Cancer Biology from University College Dublin, and a Masters of Public Health from University College Dublin. She is the author of more than 70 peer-reviewed publications and has received several awards and recognition for her work.

  • Dean Samet Square Crop - jan19.jpg
    Jon Samet, M.D., M.S.
    Dean and Professor, Colorado School of Public Health

    Jonathan M. Samet, a pulmonary physician and epidemiologist, is Dean of the Colorado School of Public Health and Professor in the departments of Epidemiology and Environmental & Occupational Health. His research has focused on the health risks of inhaled pollutants—particles and ozone in outdoor air and indoor pollutants including secondhand smoke and radon. His work on radon began in the late 1970s when he developed a still-ongoing study of New Mexico uranium miners. He led the radon component of the Biological Effects of Ionizing Radiation (BEIR) IV Committee, and chaired the National Research Council’s Radon Dosimetry Report and the BEIR VI Committee. He has served on and chaired numerous committees of the National Academies of Science, Engineering and Medicine and also the Clean Air Scientific Advisory Committee (CASAC) of the U.S. EPA and the FDA’s Tobacco Products Scientific Advisory Committee (TPSAC). Dr. Samet has served as editor and author for Reports of the Surgeon General on Smoking and Health since 1984, receiving the Surgeon General’s Medallion in 1990 and 2006 for these contributions. Dr. Samet received the 2004 Prince Mahidol Award for Global Health awarded by the King of Thailand, the Edward Livingston Trudeau Medal from the American Thoracic Society/American Lung Association, the Luther L. Terry Award for Distinguished Career from the American Cancer Society, and the Fries Prize for Health. He received the Alumni Award of Merit from the Harvard School of Public Health, and was named Distinguished Alumnus of the Year by the University of Rochester School of Medicine and Dentistry. He was elected to the National Academy of Medicine (Institute of Medicine) of the National Academy of Sciences in 1997 and received the Academy’s David M. Rall Medal for his contributions in 2015.

  • Headshot.jpg
    Peter G Shields, M.D.
    Deputy Director, Comprehensive Cancer Center; Professor, College of Medicine; Julius F. Stone Chair in Cancer Research, James Cancer Hospital; The Ohio State University Wexner Medical Center

    Dr. Peter G. Shields is currently a tenured professor in the Department of Medicine at The Ohio State University College of Medicine and in the Division of Epidemiology at the Ohio State University College of Public Health. He also is the Deputy Director of the NCI-designated Comprehensive Cancer Center (OSUCCC) and the James Cancer Hospital. His current responsibilities are to oversee the research mission of the OSUCCC, in addition to maintaining a clinical practice and a robust personal research program. Dr. Shields moved his research program to OSU from Georgetown University in 2011, where he was Professor of Oncology and Medicine and Deputy Director of the Lombardi Comprehensive Cancer Center. At Georgetown, he also was the past Interim-Chair of the Department of Medicine, Associate Director for Cancer Control and Population Sciences, and Program Leader for Cancer Genetics and Epidemiology in the Cancer Center. Dr. Shields' focus of research is on the development of phenotypes and gene-environment interactions for cancer risk, focusing on two areas, namely breast and lung cancer. The latter includes a heavy focus on the evaluation of tobacco products and biomarkers.

  • GT.jpg
    Giorgio Trinchieri, MD
    NIH Distinguished Investigator and Chief , Laboratory of Integrative Cancer Immunology, NCI

    Giorgio Trinchieri (M.D. 1973, University of Torino, Italy) is NIH Distinguished Investigator and Chief of the Laboratory of Integrative Cancer Immunology, CCR, NCI. He worked at the Basel Institute for Immunology, the Medical Genetics Institute at the Medical School of Torino, the Wistar Institute and Department of Medicine of the University of Pennsylvania, the Swiss Institute for Experimental Cancer Research and the Schering Plough Laboratory for Immunological Research (Dardilly, France). Trinchieri work has focused in innate immunity, cancer inflammation and human immunology. Trinchieri originally described the specificity of allogeneic cytotoxic T cells for class-I MHC and cross-presentation and class-I MHC restriction of tumor antigens. He contributed to the original characterization of human NK cells, described their role as innate producers of cytokines, identified type I IFNs as major activators of NK cells and discovered a new human cell type, now called plasmacytoid DC, as a major source of type I IFN in response to viruses. Trinchieri then identified the mouse counterpart of human plasmacytoid DC, paving the way for study their function in experimental mouse models of infections and tumors. Trinchieri discovered IL-12, a cytokine activating NK cells. and demonstrated its impact in innate immunity, Th-1 cell polarization, host responses to pathogens, cancer, and hematopoiesis. Recently, Trinchieri focused on the impact of cytokines and inflammation in cancer. In this field, he has demonstrated the importance of intestinal microbiota in influencing the immune responses to cancer and anti-cancer therapy in mouse models as well as in observational and interventional clinical studies.

  • Tuveson hedshot.jpg
    David Tuveson, MD, PhD
    Professor, Roy J. Zuckerberg Professor of Cancer Research, Cancer Center Director, Cold Spring Harbor Laboratory

    David Tuveson, M.D., Ph.D., FAACR is a physician scientist with a longstanding interest in understanding and treating pancreatic cancer. Dr. Tuveson is the Director of the Cancer Center and the Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory. Additionally, he is the Chief Scientist of the Lustgarten Foundation, and served as the President of the American Association for Cancer Research from 2021-2022. Dr. Tuveson obtained a bachelor’s degree in chemistry at M.I.T., followed by M.D. and Ph.D. degrees at Johns Hopkins, was a medical resident at Brigham and Women’s Hospital, and a medical oncology fellow at Dana-Farber/Harvard Cancer Center. Dr. Tuveson is known for developing the first mouse and organoid models of pancreatic cancer, and identifying subtypes of cancer associated fibroblasts. Since developing the first mouse model of pancreatic cancer in 2002, the Tuveson lab has made a series of discoveries that shed light on the molecular drivers of this disease, and provide promising therapeutic avenues for a malignancy that is notoriously challenging to treat. Dr. Tuveson was awarded the Rita Allen Scholarship, the Jan Waldenström Award, the Hamdan Award, and was elected a member of the American Society for Clinical Investigation, the Association of American Physicians, and a Fellow of the Academy of the AACR.

  • TY cropped.jpg
    Taro Yamashita, M.D.
    Associate Professor, Kanazawa University Hospital

    Taro Yamashita is a graduate of the Kanazawa University School of Medicine in 1995 and completed his Gastroenterology residency at the Kanazawa University Hospital. He spent three years as a visiting fellow at the Laboratory of Human Carcinogenesis, NCI-Bethesda, MD. He returned to Japan as an Assistant Professor of Department of Gastroenterology in 2008 and then moved to the current position in 2012. He is a member of the American Association of Cancer Research, American Association for the Study of Liver Diseases, The Japan Society of Hepatology, The Japanese Society of Gastroenterology, and The Japanese Cancer Association. He received Young Investigator Travel Award by American Association for the Study of Liver Diseases in 2004, Young Investigator Award by Gastroenterology Research Group/American Gastroenterological Association in 2005, OTSUKA Award by The Japan Society of Hepatology in 2010, Distinguished Research Award by Viral Hepatitis Research Foundation of Japan in 2011, and Invention Prize by Japan Institute of Invention and Innovation in 2013.
    His current research interests include the classification of liver cancer based on molecular profiling approaches and the development of novel diagnostics/treatment strategies targeting liver cancer stem cells.